09:08 AM EDT, 08/21/2024 (MT Newswires) -- Atossa Therapeutics ( ATOS ) said Wednesday that it had dosed the first patient in a trial evaluating its experimental drug, (Z)-endoxifen, in combination with Eli Lilly's ( LLY ) abemaciclib as a neoadjuvant treatment for certain high-risk breast cancer patients.

The study, which is part of the I-SPY network, will involve around 80 participants divided into two 40-participant cohorts and is expected to provide data by 2026.

The trial will be conducted by Atossa and Quantum Leap Healthcare Collaborative, with Atossa and Eli Lilly ( LLY ) supplying their respective drugs, Atossa said.